6. Danaher Corp. ( DHR) is a science and technology company. In August, Danaher completed the acquisition of Beckman Coulter, which makes products used in biomedical testing. The deal was a cash tender offer for all of Beckman Coulter's outstanding shares of common stock at a purchase price of $83.50 per share for a total consideration of $6.9 billion, including debt assumed and net of cash acquired. Of the 24 analysts covering Danaher, 75% rate it a buy. On average, analysts polled by Bloomberg expect the stock to gain 17.4% to $55.95 in the coming 12 months.